The Diamondback 360™ Peripheral Orbital Atherectomy System (OAS) has been well-studied in over 4,800 patients and in more than 7,000 lesions with durable results.1 In the LIBERTY 360 OAS sub-analysis, the primary patency was 89.7% at 2 years in RC2-3 patients2 and the 3-year freedom from major amputation was 88.6% in the RC6 patients.3
LIBERTY is the largest, contemporary, real-world study to evaluate procedural and long-term clinical outcomes of endovascular device interventions in patients with symptomatic lower extremity Peripheral Artery Disease (PAD).5
Peripheral Vascular Intervention (PVI) may be a reasonable treatment option across all Rutherford classes with durable results lasting to 3 years.5
A prospective, randomized, multi-center study that compared the acute and long-term results of Orbital Atherectomy System (OAS) + Percutaneous Transluminal Angioplasty (PTA) versus PTA alone in calcified below-the-knee (BTK) lesions.7
Demographics | OAS + PTA (n=25) | PTA Alone (n=25) | p-value |
---|---|---|---|
Mean Age | 70.7 ± 13.4 | 71.8 ± 10.9 | 0.75 |
Male/Female | 68%/32% | 60%/40% | 0.77 |
Diabetic Type 1 | 4% | 0% | 1.00 |
Diabetic Type 2 | 68% | 56% | 0.56 |
Renal Insufficiency (GFR <90 mL/min/1.73 m²) | 25% | 24% | 1.00 |
Smoker (current or previous) | 60% | 60% | 1.00 |
CAD | 44% | 56% | 0.57 |
Hypertension | 84% | 84% | 1.00 |
Dyslipidemia | 83% | 72% | 0.50 |
p=0.001
p=0.44
p=0.14
p=0.006
A prospective, single-arm, single-center study using Intravascular Ultrasound (IVUS) to assess Orbital Atherectomy System (OAS)-related plaque modification of femoropopliteal lesions.8
Baseline Characteristics | (n=25) |
---|---|
Age | 70.4 ± 7.8 years |
Gender (Male) | 19/25 (76.0%) |
eGFR (mL/min/1.73 m2) | 70.9 ± 25.0 |
History of diabetes (Type I or II) | 18/25 (72.0%) |
History of hyperlipidemia | 25/25 (100.0%) |
History of hypertension | 25/25 (100.0%) |
Smoker (current or former) | 21/25 (84.0%) |
Rutherford classification | 3.0 ± 0.0 |
Baseline (n=25) | 12-Month Follow-up (n-22) | p-value | |
---|---|---|---|
Rutherford Classification (RC) | <0.001 | ||
Asymptomatic (RC 0) | 0 (0.0%) | 13 (59.1%) | |
Mild Claudication (RC 1) | 0 (0.0%) | 8 (36.4%) | |
Moderate Claudication (RC 2) | 0 (0.0%) | 1 (4.5%) | |
Severe Claudication (RC 3) | 25 (100.0%) | 0 (0.0%) | |
ABI* | 0.74 ± 0.13 (n=22) | 0.95 ± 0.15 (n=21) | <0.001 |
*Greater of posterior tibial or dorsalis pedis systolic pressure divided by maximum of left or right brachial systolic pressure.
At 12 months, the freedom from target lesion revascularization (FF TLR) rate was 91.8%, and ankle-brachial index and Rutherford classification improved significantly from baseline through follow-up.
A prospective, randomized, multi-center study that compared the acute and long-term results of Orbital Atherectomy System (OAS) + Percutaneous Transluminal Angioplasty (PTA) versus PTA alone in calcified above-the-knee (ATK) lesions.9
Comorbidity | OAS + PTA (n=25) | PTA Alone (n=25) | p-value |
---|---|---|---|
Mean Age ± SD | 68.0 ± 11.0 | 71.3 ± 10.5 | 0.27 |
Female gender, n (%) | 18 (72) | 16 (64) | 0.76 |
Non-Caucasian, n (%) | 9 (36) | 4 (16) | 0.19 |
Coronary artery disease, n (%) | 12 (48) | 16 (64) | 0.39 |
Diabetes, n (%) | 18 (72) | 10 (40) | 0.05 |
Hypertension, n (%) | 22 (88) | 18 (72) | 0.29 |
Hyperlipidemia, n (%) | 23 (92) | 21 (84) | 0.67 |
Smoker (current or former), n (%) | 22 (88) | 22 (88) | >0.99 |
p<0.001
p<0.001
p<0.99
REACH PVI is a prospective, observational, single-arm, multi-center, post-market clinical study designed to prospectively evaluate acute clinical outcomes of Orbital Atherectomy (OA) via Transradial Access (TRA) for treatment of Peripheral Artery Disease (PAD) in lower extremity lesions.10
References
MAT-2314266 v1.0
Applies to Diamondback 360™ Peripheral Orbital Atherectomy System only: Including the Orbital Atherectomy Device (OAD) with GlideAssist™, Saline Pump, Viperwire Advance™ Peripheral Guide Wire, and Viperwire Advance™ with Flex Tip Peripheral Guide Wire
Applies to Diamondback 360™ Peripheral Orbital Atherectomy System – Exchangeable Series only: Including the Orbital Atherectomy Device (OAD), Handle, Orbital Atherectomy Cartridge, Saline Pump, Viperwire Advance™ Peripheral Guide Wire, and Viperwire Advance™ with Flex Tip Peripheral Guide Wire
INDICATIONS
The Diamondback 360™ Peripheral Orbital Atherectomy System/Diamondback 360™ Peripheral Orbital Atherectomy System – Exchangeable Series (OAS) is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The OAS Solid, Classic and Micro Crowns support removal of stenotic material from artificial arteriovenous dialysis fistulae (AV shunt). The system is a percutaneous orbital atherectomy system indicated as a therapy in patients with occluded hemodialysis grafts who are acceptable candidates for percutaneous transluminal angioplasty.*
*The 2.00 Max Crown has not been tested to support removal of stenotic material from artificial dialysis fistulae (AV shunt).
CONTRAINDICATIONS
Use of the OAS is contraindicated in the following situations:
WARNINGS
PRECAUTIONS
Applies to Diamondback 360™ Peripheral OAS – Exchangeable Series only:
POTENTIAL ADVERSE EVENTS
Potential adverse events that may occur and/or require intervention include, but are not limited to:
Diamondback 360™ Peripheral OAS/Diamondback 360™ Peripheral OAS– Exchangeable Series are manufactured and distributed by Cardiovascular Systems, Inc. (CSI). CSI is a subsidiary of the Abbott Group of Companies.
MAT-2303958 v1.0
Stay Connected